NCT02316470View on ClinicalTrials.gov

Dose-Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Phase II Study

PHASE2CompletedINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

May 31, 2015

Study Completion Date

October 31, 2015

Conditions
Clostridium Difficile
Interventions
BIOLOGICAL

VLA84

a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B

BIOLOGICAL

Placebo

phosphate buffered saline (PBS) solution

Trial Locations (10)

10117

Berliner Zentrum für Reise- und Tropenmedizin, Berlin

18057

Klinik und Poliklinik für Innere Medizin der Universität Rostock, Rostock

30159

KFGN Klinische Forschung Hannover- Mitte GmbH, Hanover

32934

Optimal Research LLC, Melbourne

35802

Optimal Research LLC, Huntsville

46545

Optimal Research LLC, Mishawaka

61614

Optimal Research LLC, Peoria

91911

eStudy Site, Chula Vista, Chula Vista

91942

eStudy Site, La Mesa, La Mesa

92056

eStudy Site, Oceanside, Oceanside

All Listed Sponsors
lead

Valneva Austria GmbH

INDUSTRY

NCT02316470 - Dose-Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Phase II Study | Biotech Hunter | Biotech Hunter